Senaparib

DRUG3 trials

Sponsors

Impact Therapeutics, Inc., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Fudan University

Conditions

Advanced Ovarian CancerFallopian Tube CancerOvary CancerPrimary Peritoneal Cavity CancermCRPC

Phase 2

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

Impact Therapeutics, Inc.mCRPC

Start: 2021-12-31End: 2024-08-31Target: 285Updated: 2021-12-16

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

RecruitingNCT06617923

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsFallopian Tube Cancer, Ovary Cancer, Primary Peritoneal Cavity Cancer

Start: 2025-02-06End: 2029-12-31Target: 18Updated: 2025-10-27

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

Not yet recruitingNCT07120451

Fudan UniversityAdvanced Ovarian Cancer

Start: 2025-10-10End: 2028-10-31Target: 37Updated: 2025-08-13